Nathan J Dowden Entrada Therapeutics, Inc. (TRDA) insider trading activity

Nathan J Dowden is President & COO of Entrada Therapeutics, Inc.. Currently has a direct ownership of 125,149 shares of TRDA, which is worth approximately $2.2 Million. The most recent transaction as insider was on Sep 26, 2024, when has been sold 847 shares (Common Stock) at a price of $16.0 per share, resulting in proceeds of $13,552. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 125K

0.67% 3M change

159.82% 12M change

Total Value Held $2.2 Million

Nathan J Dowden Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 26 2024	SELL Open market or private sale	$13,552 $16.0 p/Share	847 Reduced 0.67%	125,149 Common Stock
Sep 09 2024	SELL Open market or private sale	$28,693 $15.07 p/Share	1,904 Reduced 1.49%	125,996 Common Stock
Sep 06 2024	SELL Open market or private sale	$6,060 $15.19 p/Share	399 Reduced 0.31%	127,900 Common Stock
Sep 05 2024	SELL Payment of exercise price or tax liability	$2,587 $15.13 p/Share	171 Reduced 0.13%	128,299 Common Stock
Sep 04 2024	SELL Payment of exercise price or tax liability	$15,157 $15.42 p/Share	983 Reduced 0.76%	128,470 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$10,987 $16.8 p/Share	654 Reduced 0.5%	129,453 Common Stock
Aug 16 2024	SELL Open market or private sale	$446,558 $16.48 p/Share	27,097 Reduced 17.24%	130,107 Common Stock
Aug 16 2024	BUY Exercise of conversion of derivative security	$34,800 $1.74 p/Share	20,000 Added 11.29%	157,204 Common Stock
Mar 06 2024	SELL Open market or private sale	$22,496 $12.32 p/Share	1,826 Reduced 1.31%	137,204 Common Stock
Mar 05 2024	SELL Payment of exercise price or tax liability	$18,248 $12.28 p/Share	1,486 Reduced 1.06%	139,030 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$9,700 $12.9 p/Share	752 Reduced 0.53%	140,516 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	93,100 Added 39.72%	141,268 Common Stock
Sep 06 2023	SELL Open market or private sale	$13,335 $13.72 p/Share	972 Reduced 1.98%	48,168 Common Stock
Sep 05 2023	SELL Payment of exercise price or tax liability	$6,304 $14.46 p/Share	436 Reduced 0.88%	49,140 Common Stock
Sep 01 2023	BUY Grant, award, or other acquisition	-	14,200 Added 22.27%	49,576 Common Stock
Jul 11 2023	SELL Open market or private sale	$70,340 $18.05 p/Share	3,897 Reduced 9.92%	35,376 Common Stock
Jul 10 2023	SELL Open market or private sale	$57,600 $18.0 p/Share	3,200 Reduced 7.53%	39,273 Common Stock
Jun 22 2023	SELL Open market or private sale	$113,693 $16.02 p/Share	7,097 Reduced 14.32%	42,473 Common Stock
Jun 20 2023	SELL Open market or private sale	$132,741 $14.94 p/Share	8,885 Reduced 15.2%	49,570 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$11,924 $11.6 p/Share	1,028 Reduced 1.4%	72,655 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	28,400 Added 27.82%	73,683 Common Stock
Oct 31 2022	SELL Open market or private sale	$50,505 $24.05 p/Share	2,100 Reduced 4.43%	45,283 Common Stock
Oct 25 2022	SELL Open market or private sale	$196,028 $20.97 p/Share	9,348 Reduced 16.48%	47,383 Common Stock
Oct 24 2022	SELL Open market or private sale	$46,325 $19.27 p/Share	2,404 Reduced 4.07%	56,731 Common Stock
Oct 21 2022	SELL Open market or private sale	$50,682 $18.29 p/Share	2,771 Reduced 4.48%	59,135 Common Stock

NJD

Nathan J Dowden

President & COO

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Value

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA

Account